ECO Animal Health Group (LON:EAH) Reaches New 52-Week Low – Here’s What Happened

Posted by Trevor Kearing on Feb 12th, 2025

ECO Animal Health Group plc (LON:EAH – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 57.55 ($0.72) and last traded at GBX 59.45 ($0.74), with a volume of 47585 shares changing hands. The stock had previously closed at GBX 62 ($0.77).

Analysts Set New Price Targets

Separately, Shore Capital reissued a “buy” rating on shares of ECO Animal Health Group in a research note on Friday, November 29th.

Read Our Latest Report on EAH

ECO Animal Health Group Stock Performance

The company has a debt-to-equity ratio of 4.31, a quick ratio of 2.14 and a current ratio of 2.96. The company’s 50-day moving average price is GBX 67.15 and its two-hundred day moving average price is GBX 81.76. The stock has a market cap of £40.27 million, a PE ratio of 2,972.50 and a beta of -0.05.

ECO Animal Health Group (LON:EAH – Get Free Report) last issued its earnings results on Thursday, November 28th. The company reported GBX (2.50) (($0.03)) earnings per share for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 2.13%.

Insider Transactions at ECO Animal Health Group

In related news, insider David Hallas acquired 15,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were purchased at an average price of GBX 74 ($0.92) per share, with a total value of £11,470 ($14,282.16). Insiders own 21.65% of the company’s stock.

About ECO Animal Health Group

(Get Free Report)

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.